Abstract:Epilepsy Currents, Ahead of Print. Characteristics and Prognosis of Tumor-Related Epilepsy During Tumor Evolution in Patients With IDH Wild-Type Glioblastoma Pallud J, Roux A, Moiraghi A, Aboubakr O, Elia A, Guinard E, Oppenheim C, Tauziede-Espariat A, Parraga E, Gavaret M, Chrètien F, Huberfeld G, Zanello M. Neurology. 2024;102(1): e207902. doi:10.1212/WNL.0000000000207902 Background and Objectives:Tumor-related epilepsy is a well-known symptom of glioblastoma. However, the particular characteristics of epileptic seizures related to glioblastoma, isocitrate dehydrogenase (IDH)-wild-type is almost unexplored longitudinally during the whole course of the disease. We assessed tumor-related epilepsy and seizure control during tumor evolution and the prognostic significance of tumor-related epilepsy.Methods:We performed an observational, retrospective single-center study at one tertiary referral neuro-oncology surgical center (2000-2020). We included adult patients treated for a newly diagnosed supratentorial glioblastoma, IDH-wild-type with available preoperative and postoperative MRI and with available epileptic seizure status at diagnosis. To determine factors associated with tumor-related epilepsy or seizure control, univariate analyses were performed using the χ2 or Fisher exact tests for categorical variables and the unpaired t test or Mann-Whitney rank-sum test for continuous variables. Predictors associated with tumor-related epilepsy and seizure control in unadjusted analysis were entered into backward stepwise logistic regression models.Results:One thousand six patients were enrolled. The cumulative incidence of tumor-related epilepsy increased during tumor evolution (33.1% at diagnosis, 44.7% after oncologic treatment, 52.4% at progression, and 51.8% at the end-of-life phase) and is related to tumor features (cortex involvement, no necrosis, and small volume). Uncontrolled epileptic seizures increased during tumor evolution (20.1% at diagnosis, 32.0% after oncologic treatment, 46.7% at progression, and 41.1% at the end-of-life phase). Epileptic seizure control after oncologic treatment was related to seizure features (uncontrolled before oncologic treatment and focal-to-bilateral tonic-clonic seizures) and to the extent of resection. Epileptic seizure control at tumor progression was related to seizure features (presence at diagnosis and uncontrolled after oncologic treatment) and to the time to progression. Tumor-related epilepsy at diagnosis was a predictor of a longer overall survival (adjusted hazard ratio, 0.78; 95% CI 0.67-0.90; p < 0.001) independent of age, Karnofsky Performance Status score, tumor location and volume, extent of resection, standard combined chemoradiotherapy, levetiracetam use, and MGMT promoter methylation.Discussion:The progression of tumor-related epilepsy with the evolution of glioblastoma, IDH-wild-type, and the effects of surgery on seizure control argue for proper antiseizure medication and maximal safe resection. Tumor-related epilepsy is an independent predictor of a longer survival.

Seizures in glioma patients: An overview of incidence, etiology, and therapies

Pre-operative predictors of post-operative seizure control in low-grade glioma: a systematic review and meta-analysis

The course of tumor-related epilepsy in glioblastoma patients: A retrospective analysis

Seizures in low- and high-grade gliomas: current management and future outlook

The Potential of Seizure to Predict Prognosis in Glioblastoma Patients: A retrospective Study

Motor seizures confer overall survival benefit in who grade 2 glioma

Next Generation Sequencing Mutational Profiles of Gliomas Reveal Clinical and Genetic Factors Predicting Refractory Postoperative Seizures

The Clinical Features and Influencing Factors of Surgical Efficacy in Glioneuronal Tumors Associated-Epilepsy

Glioma-related epilepsy following low-grade glioma surgery

Postoperative seizure control in patients with tumor-associated epilepsy

Glioma-related epilepsy in patients with diffuse high-grade glioma after the 2016 WHO update: seizure characteristics, risk factors, and clinical outcomes

Wild Seizing Gliomas! Time-Dependent Characteristics and Prognosis of Glioblastoma-Related Epilepsy

1238 Next Generation Sequencing of Gliomas to Identify Predictors of Time to Postoperative Epilepsy

New-Onset Postoperative Seizures in Patients With Diffuse Gliomas: A Risk Assessment Analysis

Clinical Characteristics of Low‐grade Tumor‐related Epilepsy and Its Predictors for Surgical Outcome

Seizure Semiology Over Time in Adult Diffuse Glioma

Ki-67 overexpression in WHO grade II gliomas is associated with poor postoperative seizure control

Unexplained Causes of Glioma-Associated Epilepsies: A Review of Theories and an Area for Research

Ncmp-24. Glioma-Related Epilepsy: Anti-Seizure Regimens, Tolerability And Symptom Burden

Relevance for Novel Treatment Strategies in Low- and High-Grade Gliomas

Extra-temporal pediatric low-grade gliomas and epilepsy